Zacks Investment Research downgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a hold rating in a report issued on Thursday, December 21st.
According to Zacks, “LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company’s operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. “
Several other research analysts have also weighed in on the company. ValuEngine lowered LivaNova from a buy rating to a hold rating in a report on Wednesday, December 20th. BidaskClub lowered LivaNova from a strong-buy rating to a buy rating in a report on Tuesday, December 12th. Canaccord Genuity reiterated a hold rating and set a $76.00 target price on shares of LivaNova in a report on Tuesday, December 5th. Needham & Company LLC lifted their target price on LivaNova from $93.00 to $97.00 and gave the stock a buy rating in a report on Tuesday, December 5th. Finally, BTIG Research reiterated a hold rating on shares of LivaNova in a report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of $79.71.
LivaNova (LIVN) opened at $82.28 on Thursday. LivaNova has a 12-month low of $45.67 and a 12-month high of $88.56. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.03 and a quick ratio of 1.42. The stock has a market capitalization of $3,968.29, a price-to-earnings ratio of 70.33, a PEG ratio of 2.27 and a beta of 0.61.
LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.17. The business had revenue of $309.70 million for the quarter, compared to analyst estimates of $301.22 million. LivaNova had a return on equity of 9.33% and a net margin of 4.63%. The firm’s revenue was up 4.9% on a year-over-year basis. During the same period last year, the company earned $0.78 EPS. research analysts anticipate that LivaNova will post 3.24 earnings per share for the current fiscal year.
In other LivaNova news, Director Alfred J. Novak sold 2,000 shares of LivaNova stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $85.77, for a total value of $171,540.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Hugh M. Morrison sold 1,830 shares of LivaNova stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $88.00, for a total value of $161,040.00. The disclosure for this sale can be found here. Insiders sold a total of 6,830 shares of company stock worth $569,350 in the last three months. Company insiders own 0.28% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in LIVN. PNC Financial Services Group Inc. raised its stake in shares of LivaNova by 9.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock valued at $105,000 after purchasing an additional 153 shares during the period. Riverhead Capital Management LLC raised its stake in shares of LivaNova by 76.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock valued at $108,000 after purchasing an additional 763 shares during the period. Teacher Retirement System of Texas acquired a new stake in shares of LivaNova in the 2nd quarter valued at about $204,000. Shelton Capital Management acquired a new stake in shares of LivaNova in the 3rd quarter valued at about $209,000. Finally, Bessemer Group Inc. acquired a new stake in shares of LivaNova in the 2nd quarter valued at about $220,000. 86.00% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “LivaNova (NASDAQ:LIVN) Cut to “Hold” at Zacks Investment Research” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/14/livanova-livn-downgraded-to-hold-at-zacks-investment-research.html.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Get a free copy of the Zacks research report on LivaNova (LIVN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.